Published in J Biol Chem on November 11, 2005
Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc Natl Acad Sci U S A (2006) 3.04
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med (2008) 3.03
Combined IL-15/IL-15Ralpha immunotherapy maximizes IL-15 activity in vivo. J Immunol (2006) 2.69
IL-15Ralpha chaperones IL-15 to stable dendritic cell membrane complexes that activate NK cells via trans presentation. J Exp Med (2008) 2.33
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum. Blood (2012) 1.90
Trans-presentation: a novel mechanism regulating IL-15 delivery and responses. Immunol Lett (2009) 1.64
Naive CD8+ T cells differentiate into protective memory-like cells after IL-2 anti IL-2 complex treatment in vivo. J Exp Med (2007) 1.54
Mechanistic and structural insight into the functional dichotomy between IL-2 and IL-15. Nat Immunol (2012) 1.41
IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis. J Clin Invest (2010) 1.28
Hepatitis C virus (HCV) evades NKG2D-dependent NK cell responses through NS5A-mediated imbalance of inflammatory cytokines. PLoS Pathog (2010) 1.27
The influence of IL-2 family cytokines on activation and function of naturally occurring regulatory T cells. J Leukoc Biol (2008) 1.26
Functions of γC cytokines in immune homeostasis: current and potential clinical applications. Clin Immunol (2009) 1.22
IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine (2011) 1.15
Novel human interleukin-15 agonists. J Immunol (2009) 1.15
NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy. Front Immunol (2015) 1.11
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci U S A (2011) 1.10
Role of common-gamma chain cytokines in NK cell development and function: perspectives for immunotherapy. J Biomed Biotechnol (2011) 1.09
Loss of IL-15 receptor α alters the endurance, fatigability, and metabolic characteristics of mouse fast skeletal muscles. J Clin Invest (2011) 1.05
Sarcopenia, obesity, and natural killer cell immune senescence in aging: altered cytokine levels as a common mechanism. Aging (Albany NY) (2012) 1.05
Identification of a gene for an ancient cytokine, interleukin 15-like, in mammals; interleukins 2 and 15 co-evolved with this third family member, all sharing binding motifs for IL-15Rα. Immunogenetics (2013) 1.01
Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One (2014) 1.00
The IL-15-Based ALT-803 Complex Enhances FcγRIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clin Cancer Res (2015) 0.98
Comparison of the Superagonist Complex, ALT-803, to IL15 as Cancer Immunotherapeutics in Animal Models. Cancer Immunol Res (2015) 0.96
Monocytes differentiated with GM-CSF and IL-15 initiate Th17 and Th1 responses that are contact-dependent and mediated by IL-15. J Leukoc Biol (2011) 0.96
Expression of IL-15RA or an IL-15/IL-15RA fusion on CD8+ T cells modifies adoptively transferred T-cell function in cis. Eur J Immunol (2009) 0.94
Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell (2010) 0.93
Serum and muscle interleukin-15 levels decrease in aging mice: correlation with declines in soluble interleukin-15 receptor alpha expression. Exp Gerontol (2009) 0.92
Hyper-IL-15 suppresses metastatic and autochthonous liver cancer by promoting tumour-specific CD8+ T cell responses. J Hepatol (2014) 0.90
Interleukin-15:Interleukin-15 receptor α scaffold for creation of multivalent targeted immune molecules. Protein Eng Des Sel (2010) 0.88
Insights into cytokine-receptor interactions from cytokine engineering. Annu Rev Immunol (2014) 0.87
GD2-targeted immunotherapy and radioimmunotherapy. Semin Oncol (2014) 0.86
IL-15.IL-15Rα complex shedding following trans-presentation is essential for the survival of IL-15 responding NK and T cells. Proc Natl Acad Sci U S A (2014) 0.86
Liver gene transfer of interkeukin-15 constructs that become part of circulating high density lipoproteins for immunotherapy. PLoS One (2012) 0.85
MHC class I and TCR avidity control the CD8 T cell response to IL-15/IL-15Rα complex. J Immunol (2010) 0.85
Inhibition of tumor growth by NK1.1+ cells and CD8+ T cells activated by IL-15 through receptor beta/common gamma signaling in trans. J Immunol (2008) 0.83
Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from rheumatoid arthritis patients. BMC Musculoskelet Disord (2015) 0.82
Development of a quantitative bead capture assay for soluble IL-7 receptor alpha in human plasma. PLoS One (2009) 0.81
IL-2 and IL-15 signaling complexes: different but the same. Nat Immunol (2012) 0.80
IL-15Rα is a determinant of muscle fuel utilization, and its loss protects against obesity. Am J Physiol Regul Integr Comp Physiol (2015) 0.80
Paracrine and transpresentation functions of IL-15 are mediated by diverse splice versions of IL-15Rα in human monocytes and dendritic cells. J Biol Chem (2012) 0.79
IL-15 signaling promotes adoptive effector T-cell survival and memory formation in irradiation-induced lymphopenia. Cell Biosci (2016) 0.79
Mechanistic model of natural killer cell proliferative response to IL-15 receptor stimulation. PLoS Comput Biol (2013) 0.78
Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor. Biotechnol Prog (2012) 0.78
Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI. Oncoimmunology (2013) 0.77
The tumor immunosuppressive microenvironment impairs the therapy of anti-HER2/neu antibody. Protein Cell (2012) 0.77
Skeletal muscle interleukin 15 promotes CD8(+) T-cell function and autoimmune myositis. Skelet Muscle (2015) 0.76
Identification of a potent anti-IL-15 antibody with opposing mechanisms of action in vitro and in vivo. Br J Pharmacol (2011) 0.76
BTN3A molecules considerably improve Vγ9Vδ2T cells-based immunotherapy in acute myeloid leukemia. Oncoimmunology (2016) 0.76
Proinflammatory soluble interleukin-15 receptor alpha is increased in rheumatoid arthritis. Arthritis (2012) 0.76
Highly potent anti-CD20-RLI immunocytokine targeting established human B lymphoma in SCID mouse. MAbs (2014) 0.76
Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A (2016) 0.76
IL-15, in synergy with RAE-1ɛ, stimulates TCR-independent proliferation and activation of CD8(+) T cells. Oncol Lett (2011) 0.75
Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGFβ-Neutralizing Fusion Protein. Cancer Res (2016) 0.75
Immunotherapy of metastatic and autochthonous liver cancer with IL-15/IL-15Rα fusion protein. Oncoimmunology (2014) 0.75
Immunobiology of the IL-15/IL-15Rα complex as an antitumor and antiviral agent. Cytokine Growth Factor Rev (2017) 0.75
IL-15 trans-presentation promotes human NK cell development and differentiation in vivo. J Exp Med (2008) 3.03
The first alpha helix of Bax plays a necessary role in its ligand-induced activation by the BH3-only proteins Bid and PUMA. Mol Cell (2004) 2.79
Structural basis of calcification inhibition by alpha 2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J Biol Chem (2003) 2.26
The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets (2007) 2.17
Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol (2007) 2.00
Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine. J Neurosci (2005) 2.00
The nucleotide-binding oligomerization domain-like receptor NLRC5 is involved in IFN-dependent antiviral immune responses. J Immunol (2010) 1.70
Uncovering the evolutionary history of innate immunity: the simple metazoan Hydra uses epithelial cells for host defence. Dev Comp Immunol (2008) 1.55
A role for IL-27p28 as an antagonist of gp130-mediated signaling. Nat Immunol (2010) 1.44
Refinement of the binding site and mode of action of the anticonvulsant Retigabine on KCNQ K+ channels. Mol Pharmacol (2008) 1.42
Natural, proteolytic release of a soluble form of human IL-15 receptor alpha-chain that behaves as a specific, high affinity IL-15 antagonist. J Immunol (2004) 1.39
Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 1.38
Functional analysis of the osteoarthritis susceptibility-associated GDF5 regulatory polymorphism. Arthritis Rheum (2009) 1.34
PARP-10, a novel Myc-interacting protein with poly(ADP-ribose) polymerase activity, inhibits transformation. Oncogene (2005) 1.30
Inhibition of classic signaling is a novel function of soluble glycoprotein 130 (sgp130), which is controlled by the ratio of interleukin 6 and soluble interleukin 6 receptor. J Biol Chem (2011) 1.29
A novel fluorescent pH probe for expression in plants. Plant Methods (2006) 1.28
Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Hum Mol Genet (2013) 1.23
High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic melanoma and colorectal cancer. Mol Cancer Ther (2009) 1.23
Dynamics of the gp130 cytokine complex: a model for assembly on the cellular membrane. Protein Sci (2005) 1.23
Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J (2006) 1.23
Unraveling viral interleukin-6 binding to gp130 and activation of STAT-signaling pathways independently of the interleukin-6 receptor. J Virol (2009) 1.14
IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo. Proc Natl Acad Sci U S A (2011) 1.10
The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist. J Biol Chem (2002) 1.08
Signaling of human ciliary neurotrophic factor (CNTF) revisited. The interleukin-6 receptor can serve as an alpha-receptor for CTNF. J Biol Chem (2003) 1.04
Elucidating the underlying molecular pathogenesis of NR3C2 mutants causing autosomal dominant pseudohypoaldosteronism type 1. J Clin Endocrinol Metab (2006) 1.02
The exon-3-encoded domain of IL-15ralpha contributes to IL-15 high-affinity binding and is crucial for the IL-15 antagonistic effect of soluble IL-15Ralpha. J Mol Biol (2008) 1.02
Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity. J Biol Chem (2005) 1.01
An interleukin-6 receptor-dependent molecular switch mediates signal transduction of the IL-27 cytokine subunit p28 (IL-30) via a gp130 protein receptor homodimer. J Biol Chem (2012) 1.01
Human beta-defensin 2 and beta-defensin 3 chimeric peptides reveal the structural basis of the pathogen specificity of their parent molecules. Antimicrob Agents Chemother (2010) 1.01
T cell recognition of desmoglein 3 peptides in patients with pemphigus vulgaris and healthy individuals. J Immunol (2004) 1.01
Functional characterization of two novel point mutations in the CYP21 gene causing simple virilizing forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab (2004) 1.00
Caenopores are antimicrobial peptides in the nematode Caenorhabditis elegans instrumental in nutrition and immunity. Dev Comp Immunol (2009) 1.00
Hydramacin-1, structure and antibacterial activity of a protein from the basal metazoan Hydra. J Biol Chem (2008) 1.00
The structure of the interleukin-15 alpha receptor and its implications for ligand binding. J Biol Chem (2005) 0.99
N-linked glycosylation is essential for the stability but not the signaling function of the interleukin-6 signal transducer glycoprotein 130. J Biol Chem (2009) 0.98
The soluble alpha chain of interleukin-15 receptor: a proinflammatory molecule associated with tumor progression in head and neck cancer. Cancer Res (2008) 0.96
Reaction mechanism and structural model of ADP-forming Acetyl-CoA synthetase from the hyperthermophilic archaeon Pyrococcus furiosus: evidence for a second active site histidine residue. J Biol Chem (2008) 0.95
Solution structure of the pore-forming protein of Entamoeba histolytica. J Biol Chem (2004) 0.94
Congenital lipoid adrenal hyperplasia: functional characterization of three novel mutations in the STAR gene. J Clin Endocrinol Metab (2010) 0.93
The human antimicrobial protein psoriasin acts by permeabilization of bacterial membranes. Dev Comp Immunol (2009) 0.93
Forced homo- and heterodimerization of all gp130-type receptor complexes leads to constitutive ligand-independent signaling and cytokine-independent growth. Mol Biol Cell (2010) 0.93
Structure and mode of action of the antimicrobial peptide arenicin. Biochem J (2008) 0.92
Unusual function of the activation loop in the protein kinase DYRK1A. Biochem Biophys Res Commun (2003) 0.91
Extracellular Juxtamembrane Segment of ADAM17 Interacts with Membranes and Is Essential for Its Shedding Activity. Biochemistry (2015) 0.91
Structure-guided optimization of the interleukin-6 trans-signaling antagonist sgp130. J Biol Chem (2008) 0.91
Viral Interleukin-6: Structure, pathophysiology and strategies of neutralization. Eur J Cell Biol (2010) 0.91
A novel entity of clinically isolated adrenal insufficiency caused by a partially inactivating mutation of the gene encoding for P450 side chain cleavage enzyme (CYP11A1). J Clin Endocrinol Metab (2011) 0.91
Multimerisation of A disintegrin and metalloprotease protein-17 (ADAM17) is mediated by its EGF-like domain. Biochem Biophys Res Commun (2011) 0.90
Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency. Int J Cancer (2013) 0.90
Steroid 17alpha-hydroxylase deficiency: functional characterization of four mutations (A174E, V178D, R440C, L465P) in the CYP17A1 gene. J Clin Endocrinol Metab (2009) 0.90
Identification of an interleukin-15alpha receptor-binding site on human interleukin-15. J Biol Chem (2004) 0.90
The membrane-proximal domain of A Disintegrin and Metalloprotease 17 (ADAM17) is responsible for recognition of the interleukin-6 receptor and interleukin-1 receptor II. FEBS Lett (2012) 0.89
Selective blockade of CD28 and not CTLA-4 with a single-chain Fv-alpha1-antitrypsin fusion antibody. Blood (2003) 0.89
Identification of canonical tyrosine-dependent and non-canonical tyrosine-independent STAT3 activation sites in the intracellular domain of the interleukin 23 receptor. J Biol Chem (2013) 0.89
Identification and characterization of a new Leishmania major specific 3'nucleotidase/nuclease protein. Biochem Biophys Res Commun (2008) 0.89
Minimal interleukin 6 (IL-6) receptor stalk composition for IL-6 receptor shedding and IL-6 classic signaling. J Biol Chem (2013) 0.88
Congenital adrenal hyperplasia due to 11-hydroxylase deficiency: functional characterization of two novel point mutations and a three-base pair deletion in the CYP11B1 gene. J Clin Endocrinol Metab (2005) 0.88
Definition and characterization of an inhibitor for interleukin-31. J Biol Chem (2010) 0.88
Ancient weapons: the three-dimensional structure of amoebapore A. Trends Parasitol (2005) 0.88
Interleukin-6 receptor specific RNA aptamers for cargo delivery into target cells. RNA Biol (2012) 0.87
Analyzing the functional and structural consequences of two point mutations (P94L and A368D) in the CYP11B1 gene causing congenital adrenal hyperplasia resulting from 11-hydroxylase deficiency. J Clin Endocrinol Metab (2006) 0.87
Antimicrobial peptides and proteins of the horse--insights into a well-armed organism. Vet Res (2011) 0.86
Carboxyl-terminal mutations in 3beta-hydroxysteroid dehydrogenase type II cause severe salt-wasting congenital adrenal hyperplasia. J Clin Endocrinol Metab (2008) 0.86
Lipid-specific membrane activity of human beta-defensin-3. Biochemistry (2006) 0.86
Trans-sialidase-like sequences from Trypanosoma congolense conserve most of the critical active site residues found in other trans-sialidases. Biol Chem (2003) 0.86
Four novel missense mutations in the CYP21A2 gene detected in Russian patients suffering from the classical form of congenital adrenal hyperplasia: identification, functional characterization, and structural analysis. J Clin Endocrinol Metab (2006) 0.86
Membrane-proximal domain of a disintegrin and metalloprotease-17 represents the putative molecular switch of its shedding activity operated by protein-disulfide isomerase. J Am Chem Soc (2013) 0.86
Interleukin-15 and its soluble receptor mediate the response to infliximab in patients with Crohn's disease. Gastroenterology (2010) 0.86
Functional characterization of three CYP21A2 sequence variants (p.A265V, p.W302S, p.D322G) employing a yeast co-expression system. Hum Mutat (2009) 0.85
Alteration of the substrate specificity of benzoylformate decarboxylase from Pseudomonas putida by directed evolution. Chembiochem (2003) 0.84
An exceptional salt-tolerant antimicrobial peptide derived from a novel gene family of haemocytes of the marine invertebrate Ciona intestinalis. Biochem J (2008) 0.84
X-tox: an atypical defensin derived family of immune-related proteins specific to Lepidoptera. Dev Comp Immunol (2007) 0.84
Regulation of CD4(+)NKG2D(+) Th1 cells in patients with metastatic melanoma treated with sorafenib: role of IL-15Rα and NKG2D triggering. Cancer Res (2013) 0.84
Therapeutic targeting of interleukin-6 trans-signaling does not affect the outcome of experimental tuberculosis. Immunobiology (2012) 0.83
A novel bispecific single-chain antibody for ADAM17 and CD3 induces T-cell-mediated lysis of prostate cancer cells. Biochem J (2012) 0.83